09:12 AM EDT, 09/19/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that an experimental immune-based induction treatment combining Tecvayli and Darzalex Faspro showed "meaningful" efficacy in newly diagnosed, transplant-eligible multiple myeloma patients.

The company said the phase 2 trial involved 49 patients across three treatment groups using a steroid-sparing regimen and that all patients achieved at least a partial response following induction therapy.

Among 46 patients with evaluable data, the drugmaker said 100% achieved minimal residual disease negativity by cycle 6, using both next-generation flow and sequencing methods.

Additionally, 85.7% of patients achieved a complete response or better and were MRD-negative, the company said, adding that stem cell mobilization was successful in 96% of patients, with a strong median yield.

The treatment was generally well-tolerated, the company said.